May 19, 2025

Growth Disrupted in One-Third of JIA Patients, Study

In a study of 107 children with juvenile idiopathic arthritis, researchers found that one-third had growth or pubertal disturbances—often linked to disrupted hormone levels and longer disease duration.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

April 30, 2025

New AI Sensor Diagnoses Osteoarthritis and Rheumatoid Arthritis

A new AI-assisted gold sensor distinguished osteoarthritis from rheumatoid arthritis with 98.1% accuracy by analyzing synovial fluid, offering a fast, noninvasive diagnostic option, researchers report.

Conexiant

April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant

April 29, 2025

Obesity Independently Hinders Remission in RA

Study shows BMI above 30 correlates with poorer treatment outcomes regardless of comorbidities

Conexiant

April 21, 2025

Higher Dietary Acid Load Tied to Knee OA

“This study demonstrates a significant association between high DAL and increased odds of [knee] OA.”

Conexiant

April 21, 2025

Lupus Clusters Show Distinct Disease Patterns

Cluster 2 patients exhibited ‘a more severe form of the disease, marked with frequent serositis and haematological manifestations, renal and neurological involvement,’ and had poorer outcomes over time.

Conexiant

April 18, 2025

Gout Remission Linked to Lower Urate, Fewer Flares

Remission in gout after urate-lowering therapy was seldom after 1 but high after 5 years, finds a five-year NOR-Gout study tracking 211 patients.

Conexiant

April 04, 2025

First IgG4-RD Treatment Approved

A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant